Glucose

ChemistryAlso known as: Blood GlucoseAlso known as: Serum GlucoseAlso known as: Plasma Glucosemg/dL

Measures glucose concentration in peritoneal dialysis fluid after treatment.

Normal Range
70 – 100 mg/dL
mg/dL
Abnormal Levels
Consult your provider
Specimen Type
Blood

Why This Biomarker Matters

Dialysate glucose levels assess peritoneal membrane function and dialysis effectiveness. Abnormal levels indicate membrane changes affecting treatment adequacy and kidney disease management.

Understanding Your Results

Normal Range

70 – 100 mg/dL

Overview

This test measures glucose concentration in peritoneal dialysate fluid, the solution used during peritoneal dialysis for kidney failure. Glucose naturally diffuses from the dialysate into the bloodstream during treatment, and measuring residual glucose helps assess dialysate dwell time and treatment effectiveness. Changes in dialysate glucose levels can indicate peritoneal membrane changes or absorption problems affecting dialysis adequacy and treatment outcomes.

Research & Evidence

119 publications

Sort:

Research data from MEDLINE/PubMed · 119 articles

Technical Information (LOINC Codes)

Standardized laboratory codes for this biomarker

2339-0Primary
Glucose [Mass/volume] in Blood
mg/dL
2344-0
Glucose [Mass/volume] in Body fluid
mg/dL
32016-8
Glucose [Mass/volume] in Capillary blood
mg/dL
41653-7
Glucose [Mass/volume] in Capillary blood by Glucometer
mg/dL
2342-4
Glucose [Mass/volume] in Cerebral spinal fluid
mg/dL
2345-7
Glucose [Mass/volume] in Serum or Plasma
mg/dL
2350-7
Glucose [Mass/volume] in Urine
mg/dL
5792-7
Glucose [Mass/volume] in Urine by Test strip
mg/dL
2349-9
Glucose [Presence] in Urine
25428-4
Glucose [Presence] in Urine by Test strip
12629-2
Glucose [Mass/volume] in 24 hour Peritoneal dialysis fluid
mg/dL
2343-2
Glucose [Mass/volume] in Dialysis fluid
mg/dL
15075-5
Glucose [Moles/volume] in Dialysis fluid
mmol/L
33405-2
Glucose [Mass/volume] in Pericardial fluid
mg/dL
6300-8
Glucose [Mass/volume] in Amniotic fluid
mg/dL
15077-1
Glucose [Moles/time] in 24 hour Urine
mmol/(24.h)
16903-7
Glucose [Mass/volume] in Vitreous fluid
mg/dL
14745-4
Glucose [Moles/volume] in Body fluid
mmol/L
14744-7
Glucose [Moles/volume] in Cerebral spinal fluid
mmol/L
21305-8
Glucose [Mass/volume] in 24 hour Urine
mg/L
2347-3
Glucose [Mass/volume] in Peritoneal fluid
mg/dL
72516-8
Glucose [Moles/volume] in Blood by Automated test strip
umol/L
39481-7
Glucose [Moles/volume] in Arterial blood
mmol/L
59156-0
Glucose [Moles/volume] in Urine by Automated test strip
mmol/L
2348-1
Glucose [Mass/volume] in Synovial fluid
mg/dL
2351-5
Glucose [Mass/time] in 24 hour Urine
g/(24.h)
12628-4
Glucose [Mass/volume] in Peritoneal dialysis fluid
mg/dL
15074-8
Glucose [Moles/volume] in Blood
mmol/L
2346-5
Glucose [Mass/volume] in Pleural fluid
mg/dL
39480-9
Glucose [Moles/volume] in Venous blood
mmol/L
14749-6
Glucose [Moles/volume] in Serum or Plasma
mmol/L
32318-8
Glucose [Moles/volume] in Specimen
mmol/L
22705-8
Glucose [Moles/volume] in Urine by Test strip
mmol/L
50555-2
Glucose [Presence] in Urine by Automated test strip
14743-9
Glucose [Moles/volume] in Capillary blood by Glucometer
mmol/L
41651-1
Glucose [Mass/volume] in Arterial blood
mg/dL
41652-9
Glucose [Mass/volume] in Venous blood
mg/dL
2340-8
Glucose [Mass/volume] in Blood by Automated test strip
mg/dL
53328-1
Glucose [Mass/volume] in Urine by Automated test strip
mg/dL
2341-6
Glucose [Mass/volume] in Blood by Test strip manual
mg/dL
74774-1
Glucose [Mass/volume] in Serum, Plasma or Blood
mg/dL
35662-6
Glucose [Mass/volume] in Urine collected for unspecified duration
mg/dL
39478-3
Glucose [Moles/volume] in Vitreous fluid
mmol/L
39479-1
Glucose [Moles/volume] in Pericardial fluid
mmol/L
100746-7
Glucose [Moles/volume] in Mixed venous blood
mmol/L
14386-7
Glucose [Mass/volume] in Gastric fluid
mg/dL
40366-7
Glucose [Moles/time] in 24 hour Body fluid
mmol/(24.h)
105273-7
Glucose [Moles/volume] in Reporting Period mean Interstitial fluid by calculation
mmol/L
45297-9
Glucose [Moles/volume] in 24 hour Dialysis fluid
mmol/L
47620-0
Glucose [Moles/volume] in Stool
mmol/L
47995-6
Glucose [Moles/volume] in Cord blood
nmol/L
48036-8
Glucose [Mass/volume] in Stool
mg/dL
51595-7
Glucose [Presence] in Stool
51596-5
Glucose [Moles/volume] in Capillary blood
mmol/L
53050-1
Glucose [Mass/volume] in Total parental nutrition
g/L
53084-0
Glucose [Moles/volume] in Nonbiological fluid
mmol/L
54486-6
Glucose [Mass/volume] in Water
g/L
54487-4
Glucose [Moles/volume] in Water
mmol/L
55860-1
Glucose [Mass/time] in 24 hour Stool
g/(24.h)
57797-3
Glucose [Mass/volume] in Stool by Post hydrolysis
mg/dL
105272-9
Glucose [Moles/volume] in Interstitial fluid
mmol/L
58997-8
Glucose [Mass/time] in 18 hour Urine
mg/(18.h)
104655-6
Glucose [Mass/volume] in Mixed venous blood
g/dL
104598-8
Glucose [Mass/volume] in Arterial blood by Glucometer
mg/dL
104597-0
Glucose [Mass/volume] in Venous blood by Glucometer
mg/dL
74351-8
Glucose [Moles/volume] in Urine collected for unspecified duration
mmol/dL
74686-7
Glucose [Moles/time] in 12 hour Urine
mmol/(12.h)
74687-5
Glucose [Moles/volume] in 12 hour Urine
mmol/L
77135-2
Glucose [Moles/volume] in Serum, Plasma or Blood
mmol/L
93791-2
Glucose [Mass/volume] mean in Serum or Plasma
mg/dL
96594-7
Glucose [Mass/volume] in DBS
mg/dL
97507-8
Average glucose [Mass/volume] in Interstitial fluid during Reporting Period
mg/dL
99504-3
Glucose [Mass/volume] in Interstitial fluid
mg/dL
21307-4
Glucose [Mass/time] in 10 hour Urine
g/(10.h)
21306-6
Glucose [Mass/time] in 8 hour Urine
g/(8.h)
18227-9
Glucose [Mass/time] in 6 hour Urine
g/(6.h)
15076-3
Glucose [Moles/volume] in Urine
mmol/L
14750-4
Glucose [Moles/volume] in Synovial fluid
mmol/L
14748-8
Glucose [Moles/volume] in Peritoneal fluid
mmol/L
14747-0
Glucose [Moles/volume] in Pleural fluid
mmol/L
25916-8
Glucose [Moles/volume] in 24 hour Urine
mmol/L
14746-2
Glucose [Moles/volume] in Peritoneal dialysis fluid
mmol/L
32174-5
Glucose [Presence] in 24 hour Urine

Provider Perspectives

Clinical perspectives from verified healthcare providers on Glucose.

Clinical Perspective

Thread on Glycine and Blood Sugar Effects from a 2002 Study

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

Glycine, even in small amounts, can reduce blood sugar with a meal by >50% and improve insulin resistance, demonstrated in a striking study. (🧵1/7)@OutdoctrinationGlycine has some striking anti-in

Clinical Perspective

Zinc and Fatigue Reduction: Research Thread by @Outdoctrination

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

Zinc has the power to substantially reduce fatigue - here's how & why. (🧵1/7)@OutdoctrinationIt heals the gut & skin, reduces inflammation & fatigue, and massively boosts sexual health.

Clinical Perspective

Thread on NAC and Glycine Supplementation Study by @Outdoctrination

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

ANOTHER one of the most impressive studies in recent memory found that the combination of NAC + Glycine has remarkable anti-aging effects in nearly every metric. (🧵1/8)@OutdoctrinationOne of the most

Clinical Perspective

Study on Lithium Deficiency and Alzheimer's Disease Discussion

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

A groundbreaking new study shows that a mineral deficiency can drive Alzheimer's, and consuming it can reverse it. (🧵1/10)

Clinical Perspective

X Thread on NAC and ADHD Research Studies

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

N-Acetylcysteine (NAC) has the ability to substantially improve ADHD - shown in a number of different studies. (🧵1/7)@OutdoctrinationADHD is not a stimulant deficiency. The ADHD brain is substantial

Clinical Perspective

Thread on Collagen, Blood Sugar, and GLP-1 Research

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

Collagen can actually lower blood sugar and improve diabetes by increasing GLP1, shown in a surprising clinical trial. (🧵1/7)

Clinical Perspective

Vinegar's Effect on Insulin Response: Research Thread Summary

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

Vinegar at ~1 tbsp reduces insulin response by up to 50% across multiple trials, a review article concluded. (🧵1/8)

Clinical Perspective

Thread on Coconut Oil and Alzheimer's Disease Research

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

Coconut oil has some powerful protective effects for the brain and Alzheimer's disease. (🧵1/7)@OutdoctrinationAlzheimer's prevalence is set to double in the next 25 years. Yet, mainstream treatments

Clinical Perspective

Thread on Glycine and Blood Sugar Study Results

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

Glycine reduced blood sugar with a meal by >50% and improved insulin resistance in an amazing study. (🧵1/7)@OutdoctrinationThe power of GLYCINE is seemingly never-ending. For something so cheap i

Clinical Perspective

Guide to Skin Aging: Structure, Barriers, and Root Causes

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

SKIN AGING: Wrinkles, roughness, dark spots, and more. Solving it at the root cause, a COMPLETE GUIDE:

Clinical Perspective

Thread on Coconut Oil and Alzheimer's Research Claims

Dalton Graham, Founder, Prism Health - Chemical & Biomolecular Engineering · Gut Health, Bioenergetics, Mitochondrial Optimization

Coconut oil has some powerful protective effects for the brain and Alzheimer's disease. (🧵1/7)@OutdoctrinationAlzheimer's prevalence is set to double in the next 25 years. Yet, mainstream treatments